Atara Biotherapeutics
ATRA
144 hedge funds and large institutions have $910M invested in Atara Biotherapeutics in 2022 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 52 increasing their positions, 44 reducing their positions, and 17 closing their positions.
1,322% more call options, than puts
Call options by funds: $1.55M | Put options by funds: $109K
35% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 17
18% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 44
4% more funds holding
Funds holding: 139 → 144 (+5)
0.1% less ownership
Funds ownership: 4.31% → 4.21% (-0.1%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
39% less capital invested
Capital invested by funds: $1.5B → $910M (-$591M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$24.8M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$22.9M |
| 3 |
Goldman Sachs
New York
|
+$13.7M |
| 4 |
JP Morgan Chase
New York
|
+$9.84M |
| 5 |
Renaissance Technologies
New York
|
+$7.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$15.5M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$11.8M |
| 3 |
BM
Bridger Management
New York
|
-$9.72M |
| 4 |
N
Natixis
Paris,
France
|
-$7.32M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.5M |
ATRA Hedge Fund Activity: Q1 2022 in Review
144 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q1 2022, worth a combined $910M — down 39% from $1.5B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ATRA positions and 17 closed out — a net gain of 6 holders — while 52 added to existing stakes and 44 trimmed.
The largest buyer was State Street, adding an estimated $24.8M. The largest seller was Assenagon Asset Management, cutting an estimated $15.5M.
- 144 institutional investors held Atara Biotherapeutics (ATRA) as of Q1 2022, up from 139 in Q4 2021.
- Funds reported $910M of Atara Biotherapeutics stock for Q1 2022, down 39% quarter-over-quarter.
- 23 funds opened new Atara Biotherapeutics positions in Q1 2022 and 17 closed out, a net change of +6 holders.
- The largest Atara Biotherapeutics buyer in Q1 2022 was State Street, an estimated $24.8M added.
- The largest Atara Biotherapeutics seller in Q1 2022 was Assenagon Asset Management, an estimated $15.5M sold.
Based on aggregated 13F filings for Q1 2022.